FDA’s Rare Disease Day 2026 – An Event for Patients

U.S. Food and Drug Administration Rare Disease Day (virtual) · February 23, 2026

0:00/6:48

6:48:56

0:00

1:20:00

2:40:00

4:00:00

5:20:00

6:48:56

Opening remarks; urgency for rare‑disease action

Announcement

5:44 → 10:16(4m 32s)

Commissioner (speaker identified later as Marty McCary) opened Rare Disease Day emphasizing a moral duty to accelerate therapies for rare diseases and highlighted existing FDA supports (Orphan Drug Act, user‑fee waivers, priority voucher programs) and recent agency flexibilities (CMC/manufacturing flexibilities; Bayesian statistics). He previewed the plausible mechanism framework coming later in the day and urged action to move at the "speed of science."

Keywords:

Speakers:

FDA Rare Disease Day 2026 (virtual): agency leaders, center staff, patient advocates and researchers discussed FDA initiatives to accelerate rare-disease product development — including LEADER3D, the Rare Disease Innovation Hub, CBER/CDRH/CDER programs, a new "plausible mechanism" draft guidance for individualized therapies, expanded use of real‑world evidence, and AI tools for regulatory review.

AI-Generated Content: All content on this page was generated by AI to highlight key points from the meeting. For complete details and context, we recommend watching the full video. so we can fix them.

Transcript

Unlock the transcript with a paid subscription